Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

A Second Controversial Duchenne Approval For Company

 
• By Andrew McConaghie
  
FDAEntrance_1200x675
The approval went through the newly reorganized FDA Office of New Drugs
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip